Hansa Biopharma announces the first commercial kidney transplant patient treated with Idefirix in Australia Hansa Biopharma AB, announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA). AC Immune announces positive preliminary Phase 1 data […]
ReBio Pharma appointed leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer ReBio Pharma, a biotechnology company developing novel, targeted, eye- and vision-preserving therapies for ocular oncology, announced the appointment of Professor Mandeep Sagoo, MB, PhD, FRCS (Ed), FRCOphth, as Chief Medical Officer (CMO). In this role, Professor Sagoo will lead ReBio’s clinical and […]
Hansa Biopharma’s ConfIdeS Phase 3 abstract selected for ‘What’s Hot, What’s New’ plenary at ATC 2026 Hansa Biopharma AB, announced on Thursday that the ConfIdeS Phase 3 abstract titled “Superior 1-year eGFR Among Highly Sensitized Patients Desensitized with Imlifidase Compared to Control” had been selected to be highlighted at the closing plenary session “What’s Hot, What’s New” at the American Transplant Congress (ATC) 2026, which took place in Boston on June […]
